Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_218_библиотеки_им_акад_М_И_Перельмана
.pdf
161
Список литературы
333. Schachter M., Luszick J., Jäger B. et al. Safety and tolerability of moxonidine in the
treatment of hypertension // Drug Saf. 1998. Vol. 19, N. 3. P. 191–203.
334.
Schmidt-Lucke C., Rossig L., Fichtischerer S. et al. Reduced number of circulating
endothelial progenitor cells predicts future cardiovascular events: proof of concept
for the clinical importance of endogenous vascular repair // Circulation. 2005.
Vol. 111, № 22. P. 2891–2987.
335. Schols A.M.W.J., Wesseling G., Kester A.D.M et al. Dose dependent increased
mortality risk in COPD patients treated with oral glucocorticoids // Eur Respir J.
2001. Vol. 17. P. 337–342.
336. Schroeder E.B., Welch V.L., Evans G.W. et al. Impaired lung function and
subclinical atherosclerosis. e ARIC Study // Atherosclerosis. 2005. Vol. 180,
N.2. P. 367-373.
337. SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2
risk prediction algorithms: new models to estimate 10-year risk of cardiovascular
disease in Europe // Eur Heart J. 2021. Jun.
338. Seimetz M., Parajuli N., Pichl A. et al. Inducible NOS inhibition reverses
tobacco
-smoke-induced emphysema and pulmonary hypertension in mice // Cell.
2011. № 147. Р. 293
-305.
339.
Senapati A., Sperry B.W., Grodin J.L. et al. Prognostic implication of relative
regional strain ratio in cardiac amyloidosis. Heart. 2016. N. 102. P. 748–754.
340.
Sestini P., Renzoni E., Robinson S. et al. Short-acting beta 2 agonists for stable
chronic obstructive pulmonary disease // Cochrane Database Syst Rev. 2002.
Vol. 4. CD001495.
341.
Shadel G.S., Horvath T.L. Mitochondrial ROS signaling in organismal homeostasis //
Cell. 2015. N. 163. P. 560–569.
342.
Sharahaneh A., Majid H., Gross N.J. Safety and tolerability of inhalational
anticholinergics in COPD // Drug Healthc Patient Saf. 2013. Vol. 5. P. 49–55.
343. Shepard J.W. Jr., Garrison M.W., Grither D.A. et al. Relationship of ventricular
ectopy to nocturnal oxygen desaturation in patients with COPD // Am J Med. 1985.
Vol. 78, N. 1. P. 28–34.
344. Shrikrishna D., Astin R., Kemp P.R. et al. Renin-angiotensin system blockade:
a novel therapeutic approach in chronic obstructive pulmonary disease // Clin Sci
(Lond). 2012. Vol. 123, N. 8. P. 487–498.
345. Silva D. R., Gazzana M. B., Knorst M. M. C-reactive protein levels in stable COPD
patients: a case-control study // Int J Chron Obstruct Pulmon Dis. 2015. Vol. 10.
P. 1719–1725.
346. Silva G.E., Sherrill D.L., Guerra S. et al. Asthma as a risk factor for COPD in
a longitudinal study // Chest 2004. Vol. 126. P. 59–65.
https://t.me/med1917
162
Список литературы
347. Sims M.W., Panettieri R.A. Jr. Prole of aclidinium bromide in the treatment of
chronic obstructive pulmonary disease // Int J Chron Obstruct Pulmon Dis. 2011.
Vol. 6. P. 457–466.
348.
Sin D.D. e Relationship Between Reduced Lung Function and Cardiovascular
Mortality: A Population-Based Study and a Systematic Review of the Literature //
Chest. 2005. Vol. 127, N 6). P. 1952–1959.
349.
Sin D.D., Anthonisen N.R., Soriano J.B. et. al. Mortality in COPD: Role of
comorbidities // Eur Respir J. 2006. Vol. 28, N 6. P. 1245–1257.
350.
Sin D.D., Man S.F.P. Chronic Obstructive Pulmonary Disease as a Risk Factor
for Cardiovascular Morbidity and Mortality // e Proceedings of the American
oracic Society. 2005. № 2. Р. 8-11.
351. Sin D.D., Wu L., Man S.F. e relationship between reduced lung function and
cardiovascular mortality: a population-based study and a systematic review of the
literature // Chest. 2005. Vol. 127, № 6. P.1952–1959.
352. Singh D., Ferguson G.T., Bolitschek J. et al. Tiotropium + olodaterol shows clinically
meaningful improvements in quality of life // Respir Med. 2015. Vol. 109, N. 10.
P. 1312–1319.
353. Singh K.P., Lawyer G., Muthumalage T. et al. Systemic biomarkers in electronic
cigarette users: implications for noninvasive assessment of vaping-associated
pulmonary injuries // ERJ Open Research. 2019. Vol. 5(4):00182-2019.
354. Soler N., Torres A., Ewig S. et al. Bronchial microbial patterns in severe
exacerbationsof chronic obstructive pulmonary disease (COPD) requiring
mechanical ventilation // Am J Respir Crit Care Med. 1998. Vol. 157, N. 5. Pt 1.
P. 1498–1505.
355. Somers M. J., Harrison D. G. Reactive oxygen speciesand control of vasomotor
tone // Curr Hypertens Rep. 1999. Vol. 1, № 1. P. 102–108.
356. Spah F., Kottman R., Schmidt U. Eects of single intravenous administration of
urapidil and diltiazem in patients with nonxed pulmonary hypertension secondary
to chronic obstructive lung disease // J Cardiovasc Pharmacol. 1994. Vol. 23, N. 4.
P. 517–524.
357. Spira A., Beane J., Pinto-Plata V. et al. Gene expression proling of human lung
tissue from smokers with severe emphysema // Am. J. Respir. Cell Mol. Biol. 2004.
Vol. 31, № 6. P. 601–610.
358. Stead L.F., Buitrago D., Preciado N. et al. Physician advice for smoking cessation //
Cochrane Database Syst Rev. 2013. Vol. 5, N. 5. CD000165.
359. Stoller J.K., Panos R.J., Krachman S. et al. Oxygen therapy for patients with COPD:
current evidence and the long-term oxygen treatment trial // Chest. 2010. Vol. 138.
P. 179–187.
https://t.me/med1917
163
Список литературы
360. Strassmann R., Bausch B., Spaar A. et al. Smoking cessation interventions in
COPD: a network metaanalysis of randomised trials // Eur Respir J. 2009. Vol. 34.
P. 634–640.
361.
Suissa S., Patenaude V., Lapi F. et al. Inhaled corticosteroids in COPD and the risk
of serious pneumonia // orax. 2013. Vol. 68. P. 1029–1036.
362.
Sun Y., Byon C.H., Yuan K.Y. et al. Smooth muscle cell-specic runx2 deciency
inhibits vascular calcication // Circ Res. 2012. Vol. 111. P. 543–552.
363.
Sung H., Ferlay J., Siegel RL. Et al. Global Cancer Statistics 2020: GLOBOCAN
Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries //
CA Cancer J Clin. 2021. Vol. 71, N 3. P. 209-249.
364. Sung H, Johnson C.E., Lessner S.M. et al. Matrix metalloproteinase 9 facilitates
collagen remodeling and angiogenesis for vascular constructs // Tissue Engineering.
2005. Vol. 11, № 1/2. P. 267–276.
365. Suwa T., Hogg J.C., Quinlan K.B. et al. Particulate air pollution induces progression
of atherosclerosis // J Am Coll Cardiol. 2002. Vol. 39, № 6. P. 935–942.
366.
Tabara Y., Muro S., Takahashi Y. et al. Airow limitation in smokers is associated
with arterial stiness: the Nagahama Study // Atherosclerosis. 2014. Vol. 232. N. 1.
Р, 59–64.
367. Takahashi T., Kobayashi S., Fujino N. et al. Annual FEV1 changes and numbers of
circulating endothelial microparticles in patients with COPD: a prospective study //
BMJ Open. 2014. Vol. 4, № 3. P. e004571.
368. Takahashi T., Kobayashi S., Fujino N. et al. Increased circulating endothelial
microparticles in COPD patients: a potential biomarker for COPD exacerbation
susceptibility // orax. 2012. Vol. 67, № 12. P. 1067–1074.
369. Taki Y., Kinomura S., Ebihara S. et al. Correlation between pulmonary function
and brain volume in healthy elderly subjects // Neuroradiology. 2013. Vol. 55,
№ 6. P. 689–695.
370. Talhout R., Schulz T., Florek E. et al. Hazardous compounds in tobacco smoke // Int.
J. Environ. Res. Public Health. 2011. Vol. 8, № 2. P. 613–628.
371. omas R.J., Beatty A.L., Beckie T.M. et al. Home-Based Cardiac Rehabilitation:
А scientic statement from the american association of cardiovascular and
pulmonary rehabilitation, the Аmerican heart association, and the Аmerican
college of cardiology // J Cardiopulm Rehabil Prev. 2019. Vol. 39, N. 4. P. 208–225.
372. omopoulos C., Parati G., Zanchetti A. Eects of blood pressure lowering on
outcome incidence in hypertension: 4. Eects of various classes of antihypertensive
drugs--overview and meta-analyses // J Hypertens. 2015. Vol. 33. P. 195–211.
373. omopoulos C., Parati G., Zanchetti A. Eects of blood pressure-lowering on
outcome incidence in hypertension: 5. Head-to-head comparisons of various
https://t.me/med1917
164
Список литературы
classes of antihypertensive drugs– overview and meta-analyses // J Hypertens.
2015. Vol. 33. P. 1321–1341.
374.
de Torres J. P., Pinto-Plata V., Casanova C. et al. C-reactive protein levels and
survival in patients with moderate to very severe COPD // Chest. 2008. Vol. 133,
№ 6. P. 1336–1343.
375. Townsend R.R., Wilkinson I.B., Schirin E.L. et al. AHA Council on Hypertension.
Recommendations for Improving and Standardizing Vascular Research on
Arterial Stiness. A Scientic Statement from the American Heart Association //
J Hypertension. 2015. Vol. 66 N.3. Р. 698–722.
376. Traber M.G., van der Vliet A., Reznick A.Z. et al. Tobacco related diseases. Is there
a role for antioxidant micronutrient supplementation? // ClinChestMed. 2000. Vol.
21(1). e173387.
377. Uijl A., Lund L.H., Vaartjes I. et al. A registry-based algorithm to predict ejection
fraction in patients with heart failure // ESC Heart Fail. 2020. Vol. 7, N. 5.
P. 2388-2397.
378. Ulrik C.S. Once-daily glycopyrronium bromide, a long-acting muscarinic antagonist,
for chronic obstructive pulmonary disease: a systematic review of clinical benet //
Int J Chron Obstruct Pulmon Dis. 2012. Vol. 7. P. 673–678.
379. Vaes A.W., Spruit M.A., eunis J. et al. Endothelial function in patients with
chronic obstructive pulmonary disease: a systematic review of studies using ow
mediated dilatation // Expert Rev Respir Med. 2017. Vol. 11, № 12. P. 1021–1031.
380. Van den Born B.J., Lip G.Y.H., Brguljan-Hitij J. et al. ESC Council on hypertension
position document on the management of hypertensive emergencies // Eur Heart
J Cardiovasc Pharmacotherapy. 2019. Vol. 5, N. 1. P. 37–46.
381. Van Eerd E.A., van der Meer R.M., van Schayk O.C., Kotz D. Smoking cessation for
people with chronic obstructive pulmonary disease // Cochrane Database Syst Rev.
2016. Vol. 8. CD010744.
382. Van Gestel Y.R., Hoeks S.E., Sin D.D. et al. Impact of cardioselective beta-
blockers on mortality in patients with chronic obstructive pulmonary disease and
atherosclerosis // Am J Respir Crit Care Med. 2008. Vol. 178, N. 7. P. 695–700.
383. Vaneteren L.E., Spruit M.A., Wouters E.F. et al. Management of chronicobstructive
pulmonary disease beyond the lungs // Lancet Respir Med. 2016. Vol. 4. P. 911–924.
384. Vestbo J., Anderson J.A., Brook R.D. et al.; SUMMIT Investigators. Fluticasone
furoate and vilanterol and survival in chronic obstructive pulmonary disease with
heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled
trial // Lancet. 2016. Vol. 387, N. 10030. P. 1817–1826.
385. Vestbo J., Dranseld M., Anderson J.A. et al. Lange on behalf of the SUMMIT
Investigators // ERJ Open Research. 2019. Vol. 5. P. 00203-2018.
https://t.me/med1917
165
Список литературы
386. Vincken W., Aumann J., Chen H. et al. Ecacy and safety of coadministration of
once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD
patients: the GLOW6 stud // Int J Chron Obstruct Pulmon Dis. 2014. Vol. 9.
P. 215–228.
387.
Visse R., Nagase H. Matrix metalloproteinases and tissue inhibitors of
metalloproteinases: structure, function, and biochemistry // Circulation. Res. 2003.
Vol. 92, № 8. P. 827–839.
388. Visseren F.L.J., Mach F., Smulders Y.M. et al. 2021 ESC Guidelines on cardiovascular
disease prevention in clinical practice: Developed by the Task Force for
cardiovascular disease prevention in clinical practice with representatives of
the European Society of Cardiology and 12 medical societies With the special
contribution of the European Association of Preventive Cardiology (EAPC) // Eur
Heart J. 2021. Vol. 42, Issue 34. P.3227–3337.
389. Vlahos R., Bozinovski S. Glutathione peroxidase-1 as a novel therapeutic target for
COPD // Redox Report. 2013. Vol. 18, № 4. P. 142–149.
390.
Vogiatzis I., Rochester C.L., Spruit M.A. et al. American oracic Society/
European Respiratory Society Task Force on Policy in Pulmonary Rehabilitation.
Increasing implementation and delivery of pulmonary rehabilitation: key
messages from the new ATS/ERS policy statement // Eur Respir J. 2016. Vol. 47,
N. 5. P. 1336–1341.
391.
Wald D.S., Law M., Morris J.K. et al. Combination therapy versus monotherapy in
reducing blood pressure: meta-analysis on 11,000 participants from 42 trials // Am
J Med. 2009. Vol. 122. P. 290–300.
392.
Walters J.A., Smith S., Poole P. et al. Injectable vaccines for preventing pneumococcal
infection in patients with chronic obstructive pulmonary disease // Cochrane
Database Syst Rev. 2010. Vol. 11. CD001390.
393. Walters J.A.E., Walters E.H., Wood-Baker R. Oral corticosteroids for stable chronic
obstructive pulmonary disease // Cochrane Database Syst Rev. 2005. Vol. 3.
CD005374.
394. Wang B., Li R., Lu Z. Et al. Does comorbidity increase the risk of patients with
COVID-19: evidence from meta-analysis // Aging. 2020. Vol. 12, N. 7. P. 6049-6057.
395. Wedzicha J.A., Dahl R., Buhl R. et al. Pooled safety analysis of the xed-dose
combination of indacaterol and glycopyrronium (QVA149), its monocomponents,
and tiotropium versus placebo in COPD patients // Respir Med. 2014. Vol. 108.
P. 1498–1507.
396. Weis N., Almdal T. C-reactive protein– can it be used as a marker of infection in
patients with exacerbationof chronic obstructive pulmonary disease // Eur J Intern
Med. 2006. Vol. 17. P. 88–91.
https://t.me/med1917
166
Список литературы
397. Weitzenblum E., Krieger J., Apprill M. et al. Daytime pulmonary hypertension
in patients with obstructive sleep apnea syndrome // Am Rev Respir Dis. 1988.
Vol. 138, N. 2. P. 345–349.
398.
Welte T., Miravitlles M., Hernandez P. et al. Ecacy and tolerability of budesonide/
formoterol added to tiotropium in patients with chronic obstructive pulmonary
disease // Am J Respir Crit Care Med. 2009. Vol. 180. P. 741– 750.
399.
Wilchesky M., Ernst P., Brophy J.M. et al. Bronchodilator use and the risk of
arrhythmia in COPD: part 2: reassessment in the larger Quebec cohort // Chest.
2012. N. 142. P.305–311.
400. Williams B., MacDonald T.M., Morant S. et al. British Hypertension Society’s
PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and
doxazosin to determine the optimal treatment for drug-resistant hypertension
(PATHWAY-2): a randomised, double-blind, crossover trial // Lancet. 2015.
Vol. 386. P. 2059–2068.
401.
Williams B., Mancia G., Spiering W. et al. 2018 ESC/ESH Guidelines for the
management of arterial hypertension: e Task Force for the management of arterial
hypertension of the European Society of Cardiology (ESC) and the European
Society of Hypertension (ESH) // Eur Heart J. 2018. Vol. 39, N. 33. P. 3021–3104.
402. Wise R.A., Anzueto A., Cotton D. et al. Tiotropium Respimat inhaler and the risk of
death in COPD // N Engl J Med .2013. Vol. 369. P. 1491–1501.
403.
Woodward M., Brindle P., Tunstall-Pedoe H. et al. Adding social deprivation
and family history to cardiovascular risk assessment: the ASSIGN score from the
Scottish Heart Health Extended Cohort (SHHEC) // Heart. 2007. Vol. 93. № 2.
Р. 172-176.
404. World Health Organization. Noncommunicable diseases country proles. 2018.
https://www.who.int/nmh/publications/ncd-proles-2018/en.
405. Wu J., Saleh M.A., Kirabo A. et al. Immune activation caused by vascular oxidation
promotes brosis and hypertension // J Clin Invest. 2016. Vol. 126. № 1. Р. 50-67.
406. Xia N., Wang H., Nie X. Inhaled Long-Acting b2-Agonists Do Not Increase Fatal
Cardiovascular Adverse Events in COPD: A Meta-Analysis. //PLOS One. 2015. Vol.
10, N. 9. e0137904.
407. Yang I.A., Clarke M.S., Sim E.H.A. et al. Inhaled corticosteroids for stable chronic
obstructive pulmonary disease // Cochrane Database Syst Rev. 2012. Vol. 7.
CD002991.
408. Yang L., Froio R. M., Sciuto T. E. et al. ICAM-1 regulates neutrophil adhesion and
transcellular migration of TNF-alpha-activated vascular endothelium under ow //
Blood. 2005. Vol. 106, № 2. P. 584–592.
https://t.me/med1917
167
Список литературы
409. Yang Q. C., Sun X., Wang Y. M. et al. Systematic and endothelial inammation and
endothelial progenitor cell levels in emphysematous rats exposed to intermittent
hypoxia // Respir. Care. 2015. Vol. 60, № 2. P. 279–289.
410.
Yilmaz E., Canberk A., Eroglu L. Nifedipine alters serum theophylline levels in
asthmatic patients with hypertension // Fund Clin Pharmacol. 1991. Vol. 5, N. 4.
P. 341–345.
411.
Yusuf S., Hawken S., Ounpuu S. et al. Eect of potentially modiable risk factors
associated with myocardial infarction in 52 countries (the INTERHEART study):
case-control study // Lancet. 2004. Vol. 364, № 9438. P. 937–952.
412. Zakharchuk N., Nevzorova V., Brodskaya T. et al. Chronic Obstructive Pulmonary
Disease and Cardiovascular Comorbidity // J Lung Pulm Respir Res. 2018. Vol. 5,
N 1:00153.
413. Zieman S.J., Melenovsky V., Kass D.A. Mechanisms, Pathophysiology, and erapy
of Arterial Stiness // Arterioscler. romb. Vasc. Biol. 2005. Vol. 25. Р.932-943.
414.
Zhou B., Bentham J., Di Cesare M. et al. Worldwide trends in blood pressure from
1975 to 2015: a pooled analysis of 1479 population-based measurement studies with
19·1 million participants // e Lancet. 2017. Vol. 389, N 10064. P. 37–55.
415. Zhou Y., Wang X., Zeng X. et al. Positive benets of theophylline in a randomized,
double-blind, parallelgroup, placebo-controlled study of low-dose, slow-release
theophylline in the treatment of COPD for 1 year // Respirology. 2006. Vol. 11.
P. 603–610.
416. Zhou F., Yu T., Du R. et al. Clinical course and risk factors for mortality of adult
inpatients with COVID-19 in Wuhan, China: a retrospective cohort study // Lancet.
2020. Vol. 395, N. 10229. P. 1054-1062.
417. Zwerink M., Brusse-Keizer M., van der Valk P.D. et al. Self management for patients
with chronic obstructive pulmonary disease // Cochrane Database Syst Rev. 2014.
Vol. 3, N. 3. CD002990.
https://t.me/med1917
Научное издание
Невзорова Вера Афанасьевна
Бродская Татьяна Александровна
Захарчук Наталья Владимировна
Кондрашова Елена Анатольевна
ХОБЛ И АГ:
ВЕДУЩИЕ ЗВЕНЬЯ КАРДИОПУЛЬМОНАЛЬНОГО
КОНТИНУУМА
Монография
Научный редактор В.М. Черток
Редактор И.М. Забавникова
Корректор И.М. Луговая
Верстка Т.В. Петерсон
Подписано впечать 17.07.2023.
Формат 60×84/16. Усл.-печ. л. 10,5.
Тираж 100 экз. Заказ № 656.
Издательство «Медицина ДВ»
690600, г. Владивосток, пр. Острякова, 4
Отпечатано втипографии «Рея»
690074, г. Владивосток, ул. Снеговая, 13
View publication stats
https://t.me/med1917
Соседние файлы в папке Библиотека им академика М.И. Перельмана